A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia

* Aged 50 - 79 years inclusive. * Meeting the diagnosis of probable Alzheimer's Disease * Of moderate severity (Mini-Mental Status Exam \[MMSE\] score 10 - 20 inclusive). * Patients must be in generally good health as indicated by their medical history and physical examination, vital signs, electrocardiogram (ECG), and standard laboratory tests.

* Women of child bearing potential. * History or presence of a seizure disorder. * History of peptic ulcer disease, urinary or gastric retention; asthma or obstructive pulmonary disease. * History or presence of bladder outflow obstruction, gastrointestinal obstructive disorder or reduced GI motility, or narrow-angle glaucoma. * History or presence of gastrointestinal, hepatic, or renal disease, or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs. * History or presence of myasthenia. * Known hypersensitivity to donepezil, solifenacin or related drugs. * Any other clinically relevant acute or chronic diseases which could interfere with patients' safety during the trial, or expose them to undue risk, or which could interfere with study objectives. * Patients who have participated in another clinical trial with an investigational drug within previous 30 days.